Patents by Inventor William Gaarde

William Gaarde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of connective tissue growth factor expression
    Patent number: 7709630
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: May 4, 2010
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: William Gaarde, Andrew T Watt, Brett P Monia, Mausumee Guha
  • ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION
    Publication number: 20100035964
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.
    Type: Application
    Filed: January 28, 2008
    Publication date: February 11, 2010
    Inventors: William Gaarde, Andrew T. Watt, Brett P. Monia, Mausumee Guha
  • COMPOSITIONS AND THEIR USES DIRECTED TO HEPCIDIN
    Publication number: 20070275913
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and/or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.
    Type: Application
    Filed: April 12, 2007
    Publication date: November 29, 2007
    Inventors: Brett Monia, C. Bennett, William Gaarde, Trisha Lockhart, Robert McKay
  • COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA
    Publication number: 20070161593
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-?, airway hyperresponsiveness, and/or pulmonary inflammation.
    Type: Application
    Filed: October 11, 2006
    Publication date: July 12, 2007
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: James Karras, Susan Gregory, Susan Freier, William Gaarde, Mausumee Guha
  • Antisense modulation of CD40 ligand expression
    Publication number: 20060160758
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40 ligand are provided.
    Type: Application
    Filed: January 20, 2005
    Publication date: July 20, 2006
    Inventors: C. Bennett, Susan Freier, Brenda Baker, Brett Monia, Nicholas Dean, Hong Zhang, Susan Murray, Lex Cowsert, Madeline Butler, Robert McKay, Donna Ward, William Gaarde, Ian Popoff, Jacqueline Wyatt, Andrew Watt
  • Antisense modulation of MEKK4 expression
    Publication number: 20060019920
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK4. Methods of using these compounds for modulation of MEKK4 expression and for treatment of diseases associated with expression of MEKK4 are provided.
    Type: Application
    Filed: July 11, 2005
    Publication date: January 26, 2006
    Inventors: C. Bennett, Susan Freier, Brett Monia, Nicholas Dean, Hong Zhang, Robert McKay, Donna Ward, William Gaarde, Jacqueline Wyatt, Andrew Watt, Rosanne Crooke, Mark Graham, Pamela Nero, Kenneth Dobie, Alexander Borchers, Eric Marcusson, Mark Roach
  • Antisense modulation of p70 S6 kinase expression
    Publication number: 20050267063
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of p70 S6 kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding p70 S6 kinase. Methods of using these compounds for modulation of p70 S6 kinase expression and for treatment of diseases associated with expression of p70 S6 kinase are provided.
    Type: Application
    Filed: April 27, 2005
    Publication date: December 1, 2005
    Inventors: C. Bennett, Brett Monia, Susan Freier, Brenda Baker, William Gaarde, Erich Koller, Susan Murray, Andrew Watt, Jacqueline Wyatt, Pamela Nero, Mark Roach, Lex Cowsert, Kenneth Dobie
  • Antisense modulation of connective tissue growth factor expression
    Patent number: 6965025
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: November 15, 2005
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: William Gaarde, Andrew T. Watt
  • Antisense modulation of TFAP2C expression
    Publication number: 20050227938
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TFAP2C. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TFAP2C. Methods of using these compounds for modulation of TFAP2C expression and for treatment of diseases associated with expression of TFAP2C are provided.
    Type: Application
    Filed: December 17, 2004
    Publication date: October 13, 2005
    Inventors: C. Bennett, Brenda Baker, Nicholas Dean, Brett Monia, Susan Freier, James Karras, Hong Zhang, Susan Murray, Madeline Butler, Erich Koller, Thomas Condon, William Gaarde, Andrew Watt, Mark Graham, Jacqueline Wyatt, Lex Cowsert, Kenneth Dobie, Mark Roach
  • Antisense modulation of sterol regulatory element-binding protein-1 expression
    Publication number: 20050215504
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of sterol regulatory element-binding protein-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding sterol regulatory element-binding protein-1. Methods of using these compounds for modulation of sterol regulatory element-binding protein-1 expression and for treatment of diseases associated with expression of sterol regulatory element-binding protein-1 are provided.
    Type: Application
    Filed: December 16, 2004
    Publication date: September 29, 2005
    Inventors: C. Bennett, Susan Freier, Nicholas Dean, Brett Monia, William Gaarde, James Karras, Hong Zhang, Robert McKay, Donna Ward, Lex Cowsert, Erich Koller, Jacqueline Wyatt, Mark Roach, Andrew Watt, Brenda Baker, Kenneth Dobie
  • Compositions and their uses directed to transferases
    Publication number: 20050153925
    Abstract: Compounds, compositions and methods are provided for modulating the expression of hepatocyte growth factor receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding hepatocyte growth factor receptor. Methods of using these compounds for modulation of hepatocyte growth factor receptor expression and for diagnosis and treatment of disease associated with expression of hepatocyte growth factor receptor are provided.
    Type: Application
    Filed: December 16, 2004
    Publication date: July 14, 2005
    Inventors: C. Bennett, Brett Monia, Nicholas Dean, Susan Freier, Brenda Baker, Donna Ward, William Gaarde, Lex Cowsert, Andrew Watt, Kenneth Dobie
  • Antisense inhibition via RNAse H-independent reduction in mRNA
    Publication number: 20050130924
    Abstract: The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.
    Type: Application
    Filed: September 24, 2004
    Publication date: June 16, 2005
    Inventors: Brett Monia, Susan Freier, Muthiah Manoharan, William Gaarde, Richard Griffey, Eric Swayze, C. Bennett
  • Antisense modulation of connective tissue growth factor expression
    Publication number: 20050059629
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.
    Type: Application
    Filed: September 21, 2004
    Publication date: March 17, 2005
    Inventors: William Gaarde, Andrew Watt, Brett Monia, Mausumee Guha
  • Modulation of checkpoint kinase 1 expression
    Publication number: 20040097446
    Abstract: Compounds, compositions and methods are provided for modulating the expression of checkpoint kinase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding checkpoint kinase 1. Methods of using these compounds for modulation of checkpoint kinase 1 expression and for diagnosis and treatment of disease associated with expression of checkpoint kinase 1 are provided.
    Type: Application
    Filed: November 16, 2002
    Publication date: May 20, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: William Gaarde, Susan M. Freier, Kenneth W. Dobie, Andrew T. Watt
  • Antisense modulation of PPAR-delta expression
    Publication number: 20040063129
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PPAR-delta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPAR-delta. Methods of using these compounds for modulation of PPAR-delta expression and for treatment of diseases associated with expression of PPAR-delta are provided.
    Type: Application
    Filed: September 5, 2003
    Publication date: April 1, 2004
    Inventors: William Gaarde, Susan M. Freier, Andrew T. Watt
  • Antisense modulation of EDG8 expression
    Publication number: 20040014050
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of EDG8. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EDG8. Methods of using these compounds for modulation of EDG8 expression and for treatment of diseases associated with expression of EDG8 are provided.
    Type: Application
    Filed: July 19, 2002
    Publication date: January 22, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: William Gaarde, Kenneth W. Dobie
  • Antisense modulation of PPAR-delta expression
    Publication number: 20030224514
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PPAR-delta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPAR-delta. Methods of using these compounds for modulation of PPAR-delta expression and for treatment of diseases associated with expression of PPAR-delta are provided.
    Type: Application
    Filed: May 31, 2002
    Publication date: December 4, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: William Gaarde, Susan M. Freier, Andrew T. Watt
  • Antisense modulation of connective tissue growth factor expression
    Publication number: 20030144223
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.
    Type: Application
    Filed: December 10, 2001
    Publication date: July 31, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: William Gaarde, Andrew T. Watt
  • Antisense modulation of MEKK4 expression
    Publication number: 20030144242
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK4. Methods of using these compounds for modulation of MEKK4 expression and for treatment of diseases associated with expression of MEKK4 are provided.
    Type: Application
    Filed: February 21, 2003
    Publication date: July 31, 2003
    Inventors: Donna T. Ward, William Gaarde, Brett P. Monia, Jacqueline Wyatt
  • Antisense modulation of human collapsin response mediator protein 2 expression
    Publication number: 20030125274
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of human collapsin response mediator protein 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding human collapsin response mediator protein 2. Methods of using these compounds for modulation of human collapsin response mediator protein 2 expression and for treatment of diseases associated with expression of human collapsin response mediator protein 2 are provided.
    Type: Application
    Filed: November 8, 2001
    Publication date: July 3, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: William Gaarde, Andrew T. Watt